News by CNBC TV18 on TradingView, 2026-09-21 - cnbctv:d546c0336094b:0

{
  "signal_id": "f786ec7d-54d0-362a-598b-76ead1afaf5a",
  "signal_type": "news",
  "signal_subtype": "signs_new_client",
  "detected_at": "2026-09-21T08:21:02+00:00",
  "company": {
    "name": "JPMorgan",
    "domain": "jpmorgan.com"
  },
  "data": {
    "url": "https://www.tradingview.com/news/cnbctv:d546c0336094b:0/",
    "title": "News by CNBC TV18 on TradingView, 2026-09-21 - cnbctv:d546c0336094b:0 - TradingView",
    "excerpt": "JPMorgan expects 2026 to be a record year for investment banking globally, with India's initial public offering (IPO) market set to remain active over the next 12 months as large companies continue to tap public markets, according to Paul Uren, Head of Investment Banking, Asia Pacific at JPMorgan. He also expects inbound merger and acquisition (M&A) interest and corporate carve-out listings to continue, supported by global companies looking to expand their presence in India. Speaking from the sidelines of the JPMorgan India Conference, Uren said India is entering an important phase for equity capital markets, with several large IPOs currently being marketed and more companies from sectors such as consumer, healthcare and technology expected to list over the next year. He added that India's growing market depth is helping support larger offerings and secondary share sales. \"This will most likely be a record year for the investment banking industry globally,\" Uren said, adding that \"here in Asia, we expect it to be a record year that will exceed the levels of 2021.\" Uren said, \"This is a very exciting time for the Indian IPO market because there are a number of very large and prominent IPOs that are out there being marketed at the moment.\" He added that participation from international institutions, domestic investors and retail investors has helped strengthen the market and...",
    "summary": "JPMorgan advised Sun Pharma on its overseas acquisition, which is noted as the largest outbound M&A deal from India.",
    "location": "India",
    "planning": false,
    "image_url": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
    "confidence": 0.9,
    "published_at": "2026-09-21T08:21:02Z",
    "location_data": [
      {
        "region": "Southern Asia",
        "country": "India",
        "continent": "Asia",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "\"We advised on the Sun Pharma deal, which I believe is the largest outbound M&A deal from India,\" Uren said, adding that global companies are very focused on how to build a presence in India.",
    "related_company_name": "Sun Pharmaceutical Industries",
    "related_company_domain": "sunpharma.com"
  }
}

curl https://signals.autobound.ai/v1/signals/f786ec7d-54d0-362a-598b-76ead1afaf5a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jpmorgan.com","limit":20}'